CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 60 enrolled
Drug / intervention
Hydroxychloroquine +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04343768
NCT04343768Phase 2Completed
CompareCT.gov

An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial

Shahid Beheshti University of Medical Sciences·interventional·Posted Apr 13, 2020·Updated May 5, 2020

In Brief

A Phase 2 clinical trial evaluating Hydroxychloroquine, Lopinavir / Ritonavir, and 2 other interventions for COVID-19. Completed, enrolled 60 participants across 1 site.

Detailed Summary

The present study is a randomized clinical trial, with the approval of the ethics committee will be conducted on patients who have a positive test confirming COVID-19 in Loghman Hakim Medical Education Center in Tehran. Patients will be randomly assigned to the three arms of the study and after completing the course of treatment and collecting and analyzing the necessary information from each patient, the results of the study will be published both on this site and in the form of an article in a reputable international journal.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19
CountriesIran
Collaborators--

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedApr 13, 2020
Enrollment StartApr 9, 2020
Primary CompletionApr 27, 2020
TodayJul 2, 2026
Enrollment to primary: 18 daysPosted 6.2 years ago

Interventions

Hydroxychloroquinedrug

This Drug will be used in all arms.

Lopinavir / Ritonavirdrug

This Drug will be used in all arms.

Interferon Beta-1Adrug

This drug will be only used in Arm 1.

Interferon Beta-1Bdrug

This drug will be only used in Arm 2.